<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">J Med Toxicol</journal-id><journal-id journal-id-type="pmc-domain-id">1723</journal-id><journal-id journal-id-type="pmc-domain">jmedtox</journal-id><journal-title-group><journal-title>Journal of Medical Toxicology</journal-title></journal-title-group><issn pub-type="ppub">1556-9039</issn><issn pub-type="epub">1937-6995</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4057541</article-id><article-id pub-id-type="pmcid-ver">PMC4057541.1</article-id><article-id pub-id-type="pmcaid">4057541</article-id><article-id pub-id-type="pmcaiid">4057541</article-id><article-id pub-id-type="pmid">24619543</article-id><article-id pub-id-type="doi">10.1007/s13181-014-0391-6</article-id><article-id pub-id-type="publisher-id">391</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Investigation</subject></subj-group></article-categories><title-group><article-title>Safety and Efficacy of Flumazenil for Reversal of Iatrogenic Benzodiazepine-Associated Delirium Toxicity During Treatment of Alcohol Withdrawal, a Retrospective Review at One Center</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Moore</surname><given-names initials="PW">Philip W.</given-names></name><address><phone>+1-717-2318772</phone><fax>+1-717-2318435</fax><email>pwmoore@pinnaclehealth.org</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Donovan</surname><given-names initials="JW">J Ward</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burkhart</surname><given-names initials="KK">Keith K.</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Waskin</surname><given-names initials="JA">Jeffrey A.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hieger</surname><given-names initials="MA">Michelle A.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Adkins</surname><given-names initials="AR">Audrey R.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wert</surname><given-names initials="Y">Yijin</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haggerty</surname><given-names initials="DA">David A.</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rasimas</surname><given-names initials="JJ">J. J.</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Department of Internal Medicine, Harrisburg Hospital, PinnacleHealth, Harrisburg, PA 17101 USA </aff><aff id="Aff2"><label/>Department of Emergency Medicine, Pennsylvania State University College of Medicine, Hershey, PA USA </aff><aff id="Aff3"><label/>Office of Translational Sciences, Office of Clinical Pharmacology, Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD USA </aff><aff id="Aff4"><label/>Department of Emergency Medicine, Memorial Hospital, York, PA USA </aff><aff id="Aff5"><label/>Department of Emergency Medicine, Good Samaritan Hospital, Lebanon, PA USA </aff><aff id="Aff6"><label/>National Institutes of Health, NIMH, Bethesda, MD USA </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>3</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2014</year></pub-date><volume>10</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">239001</issue-id><fpage>126</fpage><lpage>132</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2015</year></date></event><event event-type="pmc-live"><date><day>01</day><month>06</month><year>2015</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2015-06-01 00:13:01.340"><day>01</day><month>06</month><year>2015</year></date></event></pub-history><permissions><copyright-statement>&#169; American College of Medical Toxicology 2014</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13181_2014_Article_391.pdf"/><abstract id="Abs1"><p>Both alcohol withdrawal syndrome (AWS) and benzodiazepines can cause delirium. Benzodiazepine-associated delirium can complicate AWS and prolong hospitalization. Benzodiazepine delirium can be diagnosed with flumazenil, a GABA-A receptor antagonist. By reversing the effects of benzodiazepines, flumazenil is theorized to exacerbate symptoms of AWS and precludes its use. For patients being treated for alcohol withdrawal, flumazenil can diagnose and treat benzodiazepine delirium without precipitating serious or life-threatening adverse events. Hospital admission records were retrospectively reviewed for patients with the diagnosis of AWS who received both benzodiazepines and flumazenil from December 2006 to June 2012 at a university-affiliated inpatient toxicology center. The day of last alcohol consumption was estimated from available blood alcohol content or subjective history. Corresponding benzodiazepine, flumazenil, and adjunctive sedative pharmacy records were reviewed, as were demographic, clinical course, and outcome data. Eighty-five patients were identified (average age 50.3&#160;years). Alcohol concentrations were detectable for 42 patients with average 261&#160;mg/dL (10&#8211;530&#160;mg/dL). Eighty patients were treated with adjunctive agents for alcohol withdrawal including antipsychotics (<italic toggle="yes">n</italic>&#8201;=&#8201;57), opioids (<italic toggle="yes">n</italic>&#8201;=&#8201;27), clonidine (<italic toggle="yes">n</italic>&#8201;=&#8201;35), and phenobarbital (<italic toggle="yes">n</italic>&#8201;=&#8201;23). Average time of flumazenil administration was 4.7&#160;days (1&#8211;11&#160;days) after abstinence, and average dose was 0.5&#160;mg (0.2&#8211;1&#160;mg). At the time of flumazenil administration, delirium was described as hypoactive (<italic toggle="yes">n</italic>&#8201;=&#8201;21), hyperactive (<italic toggle="yes">n</italic>&#8201;=&#8201;15), mixed (<italic toggle="yes">n</italic>&#8201;=&#8201;41), or not specified (<italic toggle="yes">n</italic>&#8201;=&#8201;8). Response was not documented in 11 cases. Sixty-two (72.9&#160;%) patients had significant objective improvement after receiving flumazenil. Fifty-six patients required more than one dose (average 5.6 doses). There were no major adverse events and minor adverse effects included transiently increased anxiety in two patients: 1 patient who received 0.5&#160;mg on abstinence day 2 and another patient who received 0.2&#160;mg flumazenil on abstinence day 11. This is the largest series diagnosing benzodiazepine delirium after AWS in patients receiving flumazenil. During the treatment of AWS, if delirium is present on day 5, a test dose of flumazenil may be considered to establish benzodiazepine delirium. With the limited data set often accompanying patients with AWS, flumazenil diagnosed benzodiazepine delirium during the treatment of AWS and improved impairments in cognition and behavior without serious or life-threatening adverse events in our patients.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alcohol withdrawal syndrome/delirium tremens</kwd><kwd>Benzodiazepine delirium/benzodiazepine toxicity</kwd><kwd>Hypoactive delirium/hyperactive delirium/agitated delirium</kwd><kwd>Flumazenil diagnostic/flumazenil therapeutic</kwd><kwd>Benzodiazepine/lorazepam/diazepam/midazolam</kwd><kwd>Pharmacovigilence</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; American College of Medical Toxicology 2014</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>